Investing carries serious risks, including partial or total loss of capital. Please read the Key Investment Information Sheet and the Risk factors and login before investing.
CuraVac 1A
Targeted active therapies for a world without autoimmune diseases
Key Investment Information Sheet
Terms & Conditions
DISCLAIMER
Every investment decision must be based on an examination of an exhaustive set of information provided by the entrepreneur on their online profile. Spreds only proceeds to a limited verification of this information and does not control the investment opportunity within this company. Spreds did not verify the extent to which the business plan is deemed realistic and does not intervene in determining the final terms of the investment, including the retained maximum valuation. Spreds will align itself with the financial terms negotiated with the co-investor(s).
CuraVac's Veterinary Unit - Transforming Autoimmune Treatment for Dogs
Our canine friends who have so helped prove the potential of Targeted Active Therapies are on track to benefit from this revolutionary treatment for autoimmune diseases before humans do.
CuraVac is raising funds to finalize the product development of CV-MG01 and launch its breakthrough Targeted Active Therapy (TAT) to dogs suffering from Canine Myasthenia Gravis—a crucial step toward developing novel, durable treatments to address autoimmune diseases in both animals and humans.
Following a recent positive Scientific Advice from the EMA confirming that the existing efficacy data are sufficient to support a Marketing Authorization Application in the veterinary market, CV-MG01 is poised to serve as a demonstrator of the TAT technology platform for its potential application to various autoimmune diseases.
Helping our four-legged friends in their journey to remission is only the beginning: by investing in CuraVac today, not only are you funding the product development for Canine Myasthenia Gravis, but you are also supporting the advancement of the TAT for human Myasthenia Gravis, among other diseases such as Graves’ Disease, Lupus, Type 1 Diabetes, and Multiple Sclerosis.
From Humans to Pets
Transforming Autoimmune Care with CuraVac's TAT veterinary application
CuraVac is pioneering the first targeted immunotherapy for pets, starting with Canine Myasthenia Gravis (CMG). By translating CuraVac’s clinically proven human platform into veterinary medicine, we offer a transformative solution that corrects a single underlying error rather than suppressing the entire immune system. With strong clinical validation, regulatory tailwinds, and a clear €11M+ market entry, CuraVac is positioned to lead a new era in animal healthcare, delivering both life-changing outcomes for pets and attractive returns for investors.
Problem & Unmet Veterinary Need
A Silent Threat: The High Cost and Toll of Canine Myasthenia Gravis
Canine Myasthenia Gravis (CMG) is a serious autoimmune disease that weakens the connection between nerves and muscles, greatly reducing a dog’s quality of life. Affected dogs often suffer from severe muscle weakness, difficulty swallowing, breathing problems, and loss of mobility. These symptoms frequently require expensive veterinary care, long treatment periods, and cause significant emotional stress for owners. Current treatment options are limited, mostly focused on easing symptoms, and rarely provide lasting control or remission. In many cases, the disease progresses quickly to a fatal outcome. The combination of high costs, emotional strain, and poor treatment outcomes underscores the urgent need for new, more effective therapies.
Solution: Targeted Active Therapy (TAT) for Dogs
Reprogramming Immunity: A Breakthrough Therapy That Trains, Not Suppresses
Since September 2024, EU regulations for veterinary products aimed at rare conditions in pets (affecting fewer than 0.5% of animals) have allowed for less stringent data to promote treatment for diseases that were otherwise neglected due to high development costs. Before this change, costs and regulatory burdens made it almost impossible to develop such treatments.
CuraVac’s Targeted Active Therapy (TAT) is a breakthrough approach to treating canine autoimmune diseases. Instead of broadly suppressing the immune system — as conventional therapies do, often causing side effects such as higher infection risk — TAT trains the dog’s own immune system to produce protective antibodies. These antibodies specifically neutralize the harmful ones driving the disease, while leaving the rest of the immune system intact and healthy.
Mechanism of Action
Smart Immunotherapy: Precision Antibodies That Defeat Disease Without Weakening Pets
- CuraVac’s Targeted Active Immunotherapy induces the production of specialized anti-autoimmune antibodies (Anti-Auto-Abs) that precisely target and neutralize pathogenic autoimmune antibodies causing CMG.
- Maintains the integrity and function of the general immune system.
- Delivers rapid onset of clinical improvements and sustained remission as demonstrated through results published in scientific journals.
Clinical Validation
From Suffering to Full Recovery: Proven Transformations in Real Patients
“Uto’s Journey”: Two years ago, when Uto was a 9-month-old Golden Retriever, he was diagnosed with Myasthenia Gravis and responded quickly to treatment with CV-MG01. Within 2–3 weeks, his symptoms improved significantly, and by 5–6 weeks he had achieved full remission. Remarkably, Uto has remained symptom-free for over 24 months and counting.
- Published scientific studies have robustly validated CuraVac’s veterinary TAT, showing a remission rate of 75% (15/20) (Galin et al., 2007) compared to a recently reported remission rate of 18% among 167 dogs (Dos Santos et al., 2025).
- The mean time to remission dropped dramatically, from 24 months (Dos Santos et al., 2025) to 2.4 months (Galin et al., 2007).
- Clinical trials in 25 human patients demonstrated safety and indicated efficacy.
Explanation Video: www.curavac.com/TAT-3min
Objectives & Roadmap
Fast-Track to Market Leadership: Our 5-Year Biotech Blueprint
Veterinary
Veterinary
Based on the positive Scientific Advice Report from the Committee for Veterinary Medicinal Products (CVMP) at the European Medicines Agency (EMA) confirming that sufficient efficacy data have already been collected to proceed to Marketing Authorization (July 2026).
Short-Term (2026-2027)
- Finalize the product development of CV-MG01 by manufacturing and validating a commercial batch aiming for swift regulatory approval and market entry within 2 years.
- Establish strategic veterinary healthcare partnerships for expedited market penetration and distribution.
- Scale manufacturing capacity and streamline regulatory compliance processes to ensure seamless market entry.
Mid-Term (2028-2030)
- Expand CuraVac's immunotherapy platform to additional autoimmune conditions, leveraging established scientific evidence and clinical success in CMG.
- Continue strengthening industry alliances and strategic partnerships, enhancing commercialization capabilities and veterinary market leadership.
Human
- Prepare for and conduct a phase 2 clinical trial in human patients.
- Conduct a phase 3 clinical trial in human patients.
- Submit Marketing Authorization Applications in the EU and USA.
Raise summary
| Crowd investments | €0 |
| Committed by others | €650,000 |
| Amount raised | €650,000 |
| Minimum round | €200,000 |
| Maximum round | €1,625,000 |
| Shares in the company (total round) | 6.341% |
| Pre-money valuation | €24,000,000 |
| Post-money valuation min. | €24,200,000 |
| Post-money valuation max. | €25,625,000 |